198 related articles for article (PubMed ID: 10891870)
1. Clinical uses of non-nucleoside reverse transcriptase inhibitors.
Harris M; Montaner JS
Rev Med Virol; 2000; 10(4):217-29. PubMed ID: 10891870
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
4. NNRTIs: a neglected class.
Cadman J
GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
Torre D; Tambini R; Speranza F
HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
[TBL] [Abstract][Full Text] [Related]
6. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
7. [Non-nucleoside reverse transcriptase inhibitors].
Joly V; Yeni P
Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
[TBL] [Abstract][Full Text] [Related]
8. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
Moyle G
Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
[TBL] [Abstract][Full Text] [Related]
9. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
10. The use of efavirenz as a part of late rescue antiretroviral treatment.
Manfredi R; Rizzo E; Calza L; Chiodo F
HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
[TBL] [Abstract][Full Text] [Related]
11. Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
Quiros-Roldan E; Airoldi M; Moretti F; Fausti C; Pan A; Casari S; Torti C; Castelli F; Carosi G
J Clin Lab Anal; 2002; 16(2):76-8. PubMed ID: 11948795
[TBL] [Abstract][Full Text] [Related]
12. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
13. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Zhang Z; Hamatake R; Hong Z
Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Smith PF; DiCenzo R; Morse GD
Clin Pharmacokinet; 2001; 40(12):893-905. PubMed ID: 11735608
[TBL] [Abstract][Full Text] [Related]
16. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
[TBL] [Abstract][Full Text] [Related]
17. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
18. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
Campiani G; Ramunno A; Maga G; Nacci V; Fattorusso C; Catalanotti B; Morelli E; Novellino E
Curr Pharm Des; 2002; 8(8):615-57. PubMed ID: 11945162
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
Antinori A; Zaccarelli M; Cingolani A; Forbici F; Rizzo MG; Trotta MP; Di Giambenedetto S; Narciso P; Ammassari A; Girardi E; De Luca A; Perno CF
AIDS Res Hum Retroviruses; 2002 Aug; 18(12):835-8. PubMed ID: 12201905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
